Vaxil announces key US Patent and Trademark Office Notice of Allowance for its immunotherapy

First US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago.

This will become the first US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago. ImMucin is an immunotherapy intended to train a patient's immune system, particularly T-cells and antibodies, to attack cancer cells via a specific domain, called the signal peptide, of the tumour marker MUC1. This domain bears significant advantages as an immunotherapeutic modality including its presence on approximately 90% of all cancer types. The notice indicates the patentability of claims covering the ImMucin peptide as well as claims reciting methods for treating or inhibiting cancer using the ImMucin peptide. This is a highly important addition to Vaxil's existing patent portfolio and strengthens the company's ability to protect its proprietary technologies as it continues rigorous testing and advancement of ImMucin. Moreover, it positions Vaxil as the only player able to use the 21-mer peptide known as ImMucin for all MUC1 positive tumours. Immucin is the first product generated from Vaxil's proprietary VaxHit platform, and has been awarded Orphan Drug Status from the FDA and EMA. Vaxil believes there is potential for VaxHit to generate additional immunotherapy products targeting the signal peptide domains of other prominent tumour markers.